Cargando…

Low Grade Neuroendocrine Tumors of the Lung

The lung is the second most common site of neuroendocrine tumors (NETs). Typical and atypical carcinoids are low-grade NETs of the lung. They present a favorable prognosis comported to the more common high-grade NETs. The low- and high-grade NETs require different treatment strategies; effective man...

Descripción completa

Detalles Bibliográficos
Autor principal: Melosky, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5468804/
https://www.ncbi.nlm.nih.gov/pubmed/28660170
http://dx.doi.org/10.3389/fonc.2017.00119
_version_ 1783243485983277056
author Melosky, Barbara
author_facet Melosky, Barbara
author_sort Melosky, Barbara
collection PubMed
description The lung is the second most common site of neuroendocrine tumors (NETs). Typical and atypical carcinoids are low-grade NETs of the lung. They present a favorable prognosis comported to the more common high-grade NETs. The low- and high-grade NETs require different treatment strategies; effective management of these tumors is essential to prolong survival and to manage the symptoms in patients with secretory or functional tumors. These rare tumors have received little attention and education is needed for treating physicians. This mini-review will concentrate mainly on advanced low-grade lung NETs. The article describes the classification of lung NETs and the diagnostic work-up. Different treatment methods including somatostatin analogs, peptide receptor radioligand therapy, and biologic systemic therapy are discussed. Promising results from recent trials are presented and discussed in the context of the lung primary site.
format Online
Article
Text
id pubmed-5468804
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54688042017-06-28 Low Grade Neuroendocrine Tumors of the Lung Melosky, Barbara Front Oncol Oncology The lung is the second most common site of neuroendocrine tumors (NETs). Typical and atypical carcinoids are low-grade NETs of the lung. They present a favorable prognosis comported to the more common high-grade NETs. The low- and high-grade NETs require different treatment strategies; effective management of these tumors is essential to prolong survival and to manage the symptoms in patients with secretory or functional tumors. These rare tumors have received little attention and education is needed for treating physicians. This mini-review will concentrate mainly on advanced low-grade lung NETs. The article describes the classification of lung NETs and the diagnostic work-up. Different treatment methods including somatostatin analogs, peptide receptor radioligand therapy, and biologic systemic therapy are discussed. Promising results from recent trials are presented and discussed in the context of the lung primary site. Frontiers Media S.A. 2017-06-13 /pmc/articles/PMC5468804/ /pubmed/28660170 http://dx.doi.org/10.3389/fonc.2017.00119 Text en Copyright © 2017 Melosky. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Melosky, Barbara
Low Grade Neuroendocrine Tumors of the Lung
title Low Grade Neuroendocrine Tumors of the Lung
title_full Low Grade Neuroendocrine Tumors of the Lung
title_fullStr Low Grade Neuroendocrine Tumors of the Lung
title_full_unstemmed Low Grade Neuroendocrine Tumors of the Lung
title_short Low Grade Neuroendocrine Tumors of the Lung
title_sort low grade neuroendocrine tumors of the lung
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5468804/
https://www.ncbi.nlm.nih.gov/pubmed/28660170
http://dx.doi.org/10.3389/fonc.2017.00119
work_keys_str_mv AT meloskybarbara lowgradeneuroendocrinetumorsofthelung